Breast Cancer

Tamoxifen Has No Heart-Related Effects

Published in Women's Health Weekly, January 25th, 2001

The breast cancer prevention drug, tamoxifen, does not influence cardiovascular risk in healthy women or in women with coronary heart disease, according to a study published in the January 3, 2001, issue of the Journal of the National Cancer Institute.

The study, the largest clinical trial to assess the cardiovascular risk of tamoxifen, is part of the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial.

"We found that cardiovascular event rates were not statistically significantly different between women assigned to tamoxifen or placebo, independent of pre-existing coronary heart disease," stated Steven Reis, MD,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2001-01-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry